View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Merck KGaA: Annual update

Our credit view of this issuer reflects its track record of conservative financial policies and solid cash flow generation, constrained by its currently weak late-stage pipeline.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Merck KGaA - INITIATION - Springing to Life (BUY, TP EUR150, 54pgs)

We initiate with a BUY as we show why the SpringWorks deal transforms the outlook for Merck KGaA. We show it could be 17% accretive to group EPS by 2030, driven by our ~50% above consensus sales for Gomekli & Ogsiveo and we assume significant synergies. Moreover, we show that Healthcare sales now grow 5% CAGR to 2030 & EBITDA grows 8%. This is highly likely to drive a re-rating in the Merck KGaA shares in our view. There is upside potential from label expansions. Our view on the Life Science too...

Oliver Metzger
  • Oliver Metzger
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch